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The global health community has set itself the task of eliminating tuberculosis
(TB) as a public health problem by 2050. Although progress has been made in
global TB control, the current decline in incidence of 2% yr21 is far from the
rate needed to achieve this. If we are to succeed in this endeavour, new strat-
egies to reduce the reservoir of latently infected persons (fromwhich new cases
arise) would be advantageous. However, ascertainment of the extent and risk
posed by this group is poor. The current diagnostics tests (tuberculin skin test
and interferon-gamma release assays) poorly predict who will develop active
disease and the therapeutic options available are not optimal for the scale of
the intervention that may be required. In this article, we outline a basis for
our current understanding of latent TB and highlight areas where innovation
leading to development of novel diagnostic tests, drug regimens and vaccines
may assist progress. We argue that the pool of individuals at high risk of pro-
gression may be significantly smaller than the 2.33 billion thought to be
immune sensitized by Mycobacterium tuberculosis and that identifying and
targeting this group will be an important strategy in the road to elimination.1. Introduction
Mycobacterium tuberculosis (Mtb) is a pathogen that has coevolved with anatomi-
cally modern humans [1–3], co-migrating from Africa as our population
expanded to cover every area of the globe (see box 1). It has been estimated
that in 2006 there were more cases of tuberculosis (TB) than in any other year in
recent history [7], and yet the ambitious vision adopted by the World Health
Organization (WHO) and Stop TB partnership is to eliminate TB as a public
health problem by 2050 [8]. This has been defined as achieving an incidence
rate of less than 1 case per million of the global population; for comparison, the
2012 rate is 1220 cases permillion [9]. Various regions of theworld are in different
phases of the TB epidemic and will require different strategies to make progress
towards elimination. In the twentieth century, much of Western Europe, North
America and parts of East Asia saw dramatic reductions in TB incidence through
major social and economic progress and implementation of improved TB control
and treatment programmes, with reduction in TB cases of up to 8.8% yr21 being
achieved after the second world war [10]. By contrast, sub-Saharan Africa and
Eastern Europe/Central Asia in particular suffered a steep increase in inci-
dence during the 1990s owing to the HIV epidemic and the social and
economic disruption following collapse of the Soviet Union, respectively.(a) Targeting tuberculosis
Progress recently has certainly beenmade in global TB control aided by a number
of internationally agreed targets over the last two decades. In the 1990s, as part of
theWHODOTS strategy, a commitment to identify 70% and cure 85% of TB cases
by 2005 was made, and this was largely achieved in many parts of theworld [11].
Box 1. Origins and evolution of latency in tuberculosis.
Current evidence suggests thatMtbwas already established as an infection of ancient human populations prior tomigration out
of Africa. In these small isolated hunter–gatherer populations, sustained infection would be favoured by low-virulence patho-
gens capable of persistingwithin the human host by chronic or latent infection and transmitting to susceptible new birth cohorts
years or decades after initial infection. Higher virulence pathogens with shorter incubation would result in self-terminating epi-
demics owing to elimination of susceptible hosts [2,4]. It has been speculated that increases in human population density
associated with the Neolithic Revolution in farming and the Industrial Revolution in Europe may have favoured the emergence
of Mtb strains with greater virulence and shorter incubation periods [1,3,5]. According to this model, carriage as an asympto-
matic commensal may have been the predominant mode of Mtb infection in ancient human populations and may have shaped
the natural immune response. The current predominant highmortality form of TBwould then represent a relatively recent chal-
lenge to human health. This model is consistent with phylogenetic analysis of global Mtb and with epidemiological differences
between the spread of ‘modern’ Beijing strains and that of ‘ancient’ Mycobacterium africanum [6].
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2Subsequently, as part of the response to theUnitedNationsMil-
lennium Development Goal 6 to combat HIV/AIDS, malaria
and other major diseases, the Stop TB partnership set a target
of reducing the global mortality and prevalence of TB disease
by 50% compared with 1990 levels. By 2012, a 37% reduction
in global prevalence of TB had been achieved (although not
on track to achieve 50% reduction by 2015) and a 45% reduction
in mortality (on track to achieve 50% reduction by 2015) [12].
Latest estimates suggest that in 2012 there were 8.6 million
new cases of TB and 1.3 million deaths, with the global inci-
dence of TB falling 2% yr21 over recent years [9]. In this
context, the 2050 elimination target seems particularly bold,
requiring a historically unprecedented 20% yr21 reduction in
global incidence [10]. A detailed strategy to make the 2050
vision a reality is currently being developed and will be
announced in 2014 with interim targets for 2025 and 2035
being proposed. In the initial phase, scale-up and widespread
implementation of current TB control measures coupled with
continued socioeconomic development particularly within the
BRICS (Brazil, Russia, India, China and South Africa) countries
along with continued antiretroviral therapy (ART) roll out in
sub-Saharan Africa could result in reductions in TB incidence
of 10% yr21. However, to bring global incidence down towards
current levels seen in North America and parts of Western
Europe, considered to be in the elimination phase (less than
100 cases/million yr21), by 2035 will require development of
novel technologies and approaches though research and inno-
vation. Whereas until now TB control has focused on
detection and management of active disease, which will con-
tinue to be important, a renewed focus on understanding and
managing the important reservoir of infected humans with
latent infection will be critical to future progress. Modelling
suggests that mass treatment of latent TB would be one of
the most effective ways to reduce incidence of TB [10,13], but
with current treatment and diagnostics this would involve up
to one-third of the world’s population taking three to nine
months of anti-tuberculous therapy, which is neither desirable
or feasible. In this article, we will highlight our current under-
standing of latent TB and the gaps in our knowledge that need
to be filled to developmore predictive diagnostic tests, effective
short-course treatments and vaccines.2. Diagnosing latent infection
Latent tuberculosis may be defined for convenience as that which
is unaccompanied by symptoms and physical signs, causes noobvious disturbance and is not recognised by the physician.
There is no sharp distinction between latent and manifest tuber-
culosis, and in some instances latent tuberculosis is more
extensive than that which is recognisable. Ability to distinguish
between latent and manifest disease will vary with the means
available for diagnosis. (Opie & McPhedran 1926 [14, p. 347])Opie &McPhedran’s [14] characterization of latent TB remains
accurate and insightful 88 years after writing, and it is striking
that the means physicians have available to distinguish
active and latent TB remain essentially unchanged today.
Chest X-ray, tuberculin skin testing and sputum investigation
for evidence ofMtb remain the cornerstones of diagnosis. Inter-
feron-gamma release assays developed over the last decade
represent an evolution in diagnosis of latent TB rather than a
conceptual shift as they also indicate immune sensitization.
Advanced imaging such as computed tomography (CT) and
combined positron emission tomography/computed tomo-
graphy (PET/CT) used to identify minimal disease and
invasive sampling also now play a role in specialist centres in
high-income countries in selected cases. The diagnostic path-
way nevertheless still ends in a binary classification with
those considered latently infected being potentially eligi-
ble for preventive therapy and those with active disease,
standardized treatment.
(a) The development of the tuberculin skin test
By the end of the nineteenth century, the notion that a latent
period of infection could occur in TBwaswidely accepted. Sev-
eral autopsy case series carried out around the turn of the
century demonstrated that Mtb was frequently present in per-
sons who died of causes other than TB by inoculating material
into rabbits or guinea pigs, where secondary infection was
observed [15,16]. Detecting the presence of infection in asymp-
tomatic living people was more challenging. Koch’s discovery
and development of tuberculin, a heat-killed culture filtrate of
TB that was proposed unsuccessfully as a cure in 1890, pro-
vided a useful diagnostic test, unmasking occult infection by
inducing systemic reaction following subcutaneous injection
[17]. Over a period of 60 years, thiswas refined into an intrader-
mal skin test using a standardized purified protein derivative
of tuberculin (PPD) and measuring the induration formed
after 48–72 h. The result, expressed as millimetres (mm) of
induration, is a continuous variable where the threshold for a
positive result can be varied to modify diagnostic sensitivity
and specificity. The dose of PPD was optimized to maximize
sensitivity in distinguishing healthy close contacts of TB from
healthy non-contacts, and the tuberculin skin test (TST) remains
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3widely used globally today and is generally considered to
demonstrate the presence of infection [18].
But to what extent can this relationship be assumed to be
true in the obvious absence of autopsy studies to relate premor-
bid TST to post-mortem identification of viable bacilli? The
guinea pig ‘natural infection’ model, initially developed by
Riley to investigated airborne transmission in which air from
side rooms or wards where TB-infected patients are resident
is vented over chambers housing guinea pigs, can provide
some evidence. In these studies, the distribution and magni-
tude of TST reactions found in guinea pigs was similar to
humans; at autopsy, evidence of infection was found in 0% of
guinea pigs with tuberculin reactions of 0–5 mm (negative
reaction), 92% of guinea pigs with TST of 14 mm or more or
evidence of necrosis, but only 25% with TST of 6–13 mm [19].
This finding, that not all ‘naturally infected’ guinea pigs with
positive TST have evidence of infection at autopsy, was sub-
sequently confirmed by others [20,21]. Equally, if positive TST
indicated presence of infection and negative TST absence of
infection, then treatment of latent infection might be expected
to cause a reversion of status. In the United States Public
Health Service Trials 13 176 household contacts who were
initially tuberculin reactors had TST repeated at 12 months;
6.5% of contacts who received placebo converted to negative
and 7.9% of isoniazid treated subjects converted to negative.
However, isoniazid reduced the 10-year incidence of TB by
59% in those that remained TST positive at 12 months and by
38% in those that converted at 12months, indicating that isonia-
zid’s efficacy to prevent disease was not associated with a
capacity to induce TST reversion [22]. From this, we conclude
that TST provides evidence of immune sensitization by Mtb
and is a correlate of TB infection but usually remains positive
even if infection is treated.
Because TST can register low-level false positive results due
to sensitization by environmental bacteria and BCG, interferon
(IFN)-gamma release assays (IGRAs) were developed to
improve specificity of the diagnosis. While these tests provide
a reasonably good measure of TB exposure and their negative
predictive values are very high (IGRA 99.7%, TST 99.4%),
they are, like TST, poorly predictive of progression to active dis-
ease (positive predictive value: IGRA 2.7%, TST 1.5%) [23,24].
As a result, when these immunodiagnostic tests are used
as a guide for administration of preventive therapy, the
number needed to treat (NNT) to prevent one case of active
TB is high. In a systematic review of 11 studies involving
73 375 HIV-uninfected participants where presence of infec-
tion was mainly determined by TST and participants were
randomized to isoniazid or placebo, the pooled NNT was
100, ranging from 36 in recently infected household contacts
and up to 179 in those remotely infected [25]. After the initial
need to develop sensitive and then specific tests for latent TB,
we now need to develop tests that are better able to predict
who will develop active TB.3. Estimating the global burden of latent
tuberculosis
Defining the prevalence of infection at a global and a regional
level is critical to understanding the potential size of the
reservoir of infection and planning intervention strategies.
One of the most widely quoted statistics is that one-third of
the world’s population is infected by Mtb, emphasizing thehuge scale of the problem [26]. However, no test actually
demonstrates the presence of infection and it is useful to con-
sider the data upon which the statement is made. Prevalence
of infection in a population is not directly estimated frompopu-
lation-wide tuberculin surveys but derived from the annual
rate of infection (ARI), which can be either directly determined
from focused tuberculin surveys (usually in school children) or
indirectly estimated from incidence of active TB (itself usually
estimated from case notification, disease prevalence or mor-
tality data), using the equation ARI ¼ incidence/coefficient,
as risk of infection is determined by contact with infectious
cases [27]. In addition, the change in ARI over time should
be known in order to accurately determine prevalence of
infection throughout the population.
In 1999, WHO convened a consensus group comprising 86
experts and epidemiologists who evaluated the best available
data for all countries up to 1997 for a number of TB indicators
including prevalence of infection [26]. Recent good quality
tuberculin surveys were available for only 24 countries and
the rate of change in ARI was only accurately known in a min-
ority. For the majority of countries for which good quality
tuberculin surveys were not available (or it was not possible
to confidently extrapolate from countries with good data),
ARI was derived from the incidence of smear positive disease
using the equation abovewith the coefficient of 50 (for countries
where HIV prevalence in TB cases was less than 5%) coming
from ‘Styblo’s rule’ [28] (which states that a smear positive pul-
monary TB incidence of 50/100 000 yr21 corresponds to ARI of
1%, potentially an overestimate—vide infra). The authors esti-
mated that 32% of the world’s population was infected with
Mtb but acknowledged the lack of good data and limitations
of the models to determine prevalence of infection and did
not provide an uncertainty estimate.
Tuberculin surveys, while widely performed and a poten-
tially cost effective way to monitor changes in the burden of
infection, have several limitations. Aside from the inherent issue
of observer variability, interpreting results to determine the pro-
portion that are immune sensitized by Mtb is challenging as the
specificity of the test varies between populations depending
upon exposure to environmental mycobacteria and BCG vacci-
nation. Analysing the distribution of TST reactions using
mixture models and other techniques to identify bimodal pat-
terns (as the reaction to TST is greater following immune
sensitization by Mtb than environmental mycobacteria or BCG)
can be performed but not all distributions lend themselves to
this form of analysis [29,30]. Systematic surveys using IGRA
have not often been performed and the need for venepuncture,
specialist laboratories and cost may limit widespread use. In
addition, the dynamics of IGRA conversion and reversion over
time and hence sensitivity to detect remote infection are less
well understood, although data from IGRA surveys could be
used with tuberculin surveys to refine estimates of latent TB
infection (LTBI) prevalence [31]. A recombinant ESAT-6/
CFP-10 skin test is currently in development with early clinical
studies showing superior specificity to TST and correlation
with whole blood Quantiferon results [32]; such a test may
ultimately prove particularly useful for surveys of this kind.
Modelling the risk of infection from the incidence of smear
positive active disease seems appropriate but ‘Styblo’s rule’
makes some key assumptions informed by six studies between
1921 and1971: each smearpositive incident case is infectious for
2 years (corresponding to two prevalent cases), and each preva-
lent case results in 10 new infections per year.Hence the rule, an
7 billionknown unknown
? degree of protection
from re-infection by Mtb
? immune sensitized at
some stage but reverted
? high risk of active TB
ª2.33 billion TST +ve
8.6 million active TB/yr
Figure 1. Reservoir of TB—we currently have estimates for proportion of population that are immune sensitized (large circle) and number of cases of active TB annually
(small filled circle). As TST and IGRA reversion can occur, total number of exposed persons may be greater than this (larger dashed circle), in addition TST and IGRA are
only moderately sensitive for active TB. A much smaller pool of people may be at much higher risk of TB (bottom small dashed circle) and also a proportion of people
may receive considerable protection against reinfection (top small dashed circle). Identifying these additional populations may be very valuable. (Online version in colour.)
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4incidence of 50/100 000 yr21 results in an infection rate of 1000/
100 000 yr21. This may be less applicable in the contemporary
era as improved diagnosis and treatment may have reduced
the average duration of infectiousness significantly and factors
such as population density, success of TB control programmes,
the prevalence of HIV infection and the prevalence of drug-
resistant TB will also have influenced transmission [33]. A
recent analysis of data from East Asian countries between
1975 and 1994 by van Leth et al. [34] determined that the
number of infections per prevalent smear positive case was
2.6–5.9 yr21, so at least in some parts of the world ‘Styblo’s
rule’ overestimates infection [33,34]. Smear positive TB is also
not homogeneous. Jones-Lopez et al. [35] have shown that in
only 45% of smear positive cases could Mtb be cultured from
cough aerosols generated through 10 min of strong coughing.
In addition, the variability in colony-forming units (cfu) gener-
ated was great (1–378 cfu). They also showed that infection of
household contacts was significantly greater when the index
cases had a high cough aerosol cfu compared with low or no
cough aerosol cfu [35]. Confirming that cases of TB transmit vari-
ably, Escombe et al. [36] using the Riley guinea pig model of
airborne infection in an HIV/TB ward in Peru showed that
8.5% of admissions were responsible for 98% of infections in
guinea pigs. Further complicating the situation is the fact that
although previously Mtb was considered a highly invariant
pathogen, recent large-scale whole genome sequencing projects
have made it clear that the pathogen has continued to evolve.
As human population density has expanded exponentially and
living conditions have shifted from low-density agrarian con-
ditions to high-density urban conditions, new genetic variants
of Mtb have emerged, displacing formerly resident strains [37]
(see box 1). More ‘modern’ strains differ from their ancient pro-
genitors, notably at a cellular level in the magnitude of the
innate immune response they elicit [38]. More variation in
these strains has been observed than previously expected, and
plausible links to enhanced transmissibility have been inferredfrom cluster size in human populations exposed to multiple
strain clades [39].Comparisonofexperimental infectionoutcome
in non-human primates withmodern and ancient strains reveals
strikinglydifferentoutcomesof infectionamongcurrentlypreva-
lent clades [40]. The contribution of strain variability to
differences in transmissibility is likely tobegeographyandpopu-
lation-density specific, and employing any general rule to
establish prevalence of infection base on reported cases is likely
to be extremely inaccurate.
Accurate estimation of the proportion of the world that
is infected using the currently available tools is extremely diffi-
cult. Better data and a better understanding of how parameters
change regionally or in certain situations (such as drug resist-
ance) may allow for the development of more sophisticated
models [41] that will allow more accurate assessment of the
prevalence of infection and estimates of useful subgroups
such as the prevalence of drug-resistant LTBI or the proportion
of LTBI related to a recent infection. However, ultimately what
we want to know is the proportion that is highly likely to
develop active disease (figure 1).4. The natural history of tuberculosis
The natural history of TB is more complex than most bacterial
pathogens. The incubation period is prolonged and the out-
come of infection variable depending upon both host and
pathogen. Much of our current understanding still arises
from piecing together historical studies and evidence from
animal models that often fail to replicate key aspects of
human disease. However, understanding this natural history
of infection is critical to accurate categorization of TB-infected
persons, identification of correlates of risk and protection,
and development of novel interventions.
Although TB can develop in virtually any part of the
body, disease involving the lungs (which occurs in 60–75%
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Figure 2. Incidence of TB in household contacts of TB treated with isoniazid
or placebo over 10 years by TST status (TST 2ve less than 5 mm). Based on
data for 26 833 persons from Ferebee [22].
rstb.royalsocietypublishing.org
Phil.Trans.R.Soc.B
369:20130437
5of cases) is necessary for transmission of infection, in particu-
lar pulmonary cavitation facilitates efficient Mtb replication
and transmission. There is some evidence that suggests Mtb
may specifically exploit the immune response through con-
servation of immunodominant epitopes [42], which could
promote the induction of immunopathology that leads to
lung cavitation. It is immunocompetent adults that contribute
most to disease transmission. These individuals who are most
effective at transmitting are often sputum smear positive and
cough spontaneously, thereby generating infectious particles.
Infection is initiated by droplet nuclei of less than 5 mm that
can remain suspended in the air for hours (if not disrupted by
turbulence) and be inhaled by contacts sharing the same
environment [43]. Around 30–50% of close household con-
tacts will develop evidence of immune sensitization as a
result of infection [44].
A single droplet nucleus (probably containing 1–10 bacilli)
can initiate infection, with the site of implantation following
chance distribution strongly influenced by the particle size
across the lung lobes [45]. The early stages of infection are
characterized by a localized macrophage-rich alveolitis, lym-
phatic spread to regional mediastinal lymph nodes and a
low-grade bacillaemia allowing distant dissemination [46,47].
Approximately 2–10 weeks following initial infection, a cell-
mediated immune response develops, signified by tuberculin
conversion, facilitating the development of granulomas
which promote control of infection [48] (box 2). This initial
infection is often asymptomatic but may be associated with
fever, mild chest symptoms and increased inflammatory mar-
kers [52,53]. The primary infiltrate may be visible on chest
radiograph in 2–6% of older children and adults [54] (this
may be considerably higher in young children [55,56]). In a
small proportion (less than 15%), the visible primary infiltrate
may progress (progressive primary TB), but in general the
lesion heals and often eventually calcifies. If progressive TB
disease subsequently develops within the lungs, it does so at
a distant site, most commonly arising apically or sub-apically;
the mechanism for this characteristic localization is poorly
understood and the source of some speculation [57–59].(a) Lifetime risk of infection progressing to disease
The lifetime age-weighted risk of TB following infection in set-
tings with low exogenous reinfection is estimated to be 12%
[60]. Careful follow-up in placebo-controlled intervention
studies has demonstrated that disease is most likely to occur
in the first year following infection, with stepwise reduction
year on year over the following 5–10 years (figure 2), by
which time incidence approaches that of uninfected contacts
[22]. The different manifestations of TB occur at different inter-
vals following infection, with pleural TB, TB meningitis and
miliary TB occurring after a shorter interval than pulmonary
or other extra-pulmonary sites.
Reactivation several decades after initial infection occurs
[61], but as observational studies with close follow-up
rarely continue beyond 10 years it is difficult to assess how
common reactivation is outside this timeframe. In addition,
conventional observational studies make it difficult to evalu-
ate whether disease relates to the initial infection event or
subsequent reinfection. Borgdorff et al. [62] applied a molecu-
lar epidemiology approach (using restriction fragment length
polymorphism of IS6110 þ/2 polymorphic GC-rich
sequence) to 12 222 cases of TB over a 15-year period in theNetherlands and identified 1095 linked secondary cases
from 688 source cases. The median incubation period (time
between predicted date of infection and onset of symptoms
in the secondary case) was calculated to be 1.26 years, and
the serial interval (time between symptom onset in source
and secondary case) was found to be 1.44 years with 83%
of secondary cases occurring within 5 years of the source
case and more than 95% within 10 years [62].
Studies of immigrants from high to low burden countries
provide further insight. Risk of TB is especially high in the
first few years following migration, but migrants remain at
higher risk of TB for decades after entry [63]. It is difficult
to establish whether this relates to delayed reactivation or
(re)infection following recent transmission either from visit-
ing country of origin or from the local community.
However, McCarthy [64] has shown that diagnosing TB in
migrants is very rare more than 15 years after arrival if they
have low risk of re-exposure. In this study, of 230 migrants
from high burden countries in Asia diagnosed with TB in
London in the 1980s (low burden setting), 10.4% had arrived
in the UK 11–15 years previously and 5.6% more than 15
years previously; however, in those who had never returned
to Asia since migrating and had no known UK TB contact,
only 3.9% had arrived 11–15 years previously and 0.8%
more than 15 years previously [64].
Furthermore, the observation that the elderly in low TB
burden settings have a higher incidence of TB is often, possibly
incorrectly, interpreted as providing evidence of prolonged
latency and reactivation following immunosenescence. How-
ever, careful evaluation of birth cohorts shows that this
apparent increased risk is an artefact of falling transmission,
and younger adults are still invariably at greater risk of TB
than the elderly [65]. These data show that the common view
that reactivation TB disease often occurs decades after initial
infection may be overstated; the majority of cases occur
within 18 months of infection and disease resulting from reacti-
vationmore than 10 years after infectionmay be rare. The risk of
disease is also not constant over time; following a single
Box 2. The nature of Mtb in latent infection.
Mtb adapts to environmental triggers such as hypoxia, nutrient starvation and reduced pH encountered during infection by
altering metabolism and arresting replication [49]. Adaptation often includes transient transcriptional activation of a charac-
teristic set of approximately 50 genes under the control of the DosR ‘dormancy’ regulator, together with additional genes
appropriate to the specific environmental cue [50]. The products of these induced genes are currently being explored as
potential biomarkers. Resumption of replication following exposure to a more favourable environment is presumed to
involve analogous transcriptional and metabolic reprogramming, including cell wall changes mediated by a family of trans-
glycosylase enzymes [51]. The ability of Mtb to persist in a reversible non-replicating state is a key virulence factor but the
direct equation of clinical latency with non-replicating mycobacteria and active disease with replicating mycobacteria is an
oversimplification. Although active disease is characterized by uncontrolled increases in bacillary numbers, imaging and
autopsy studies show that there are numerous micro-environments that exhibit varying degrees of progression and healing.
A partially overlapping heterogeneous spectrum is seen in latent stages of infection. The prolonged courses of treatment
required to prevent relapse following treatment of active TB are thought to be due to persistent populations of bacilli,
whereas the efficacy of isoniazid as preventive therapy in latent infection is thought to be due to its effect on replicating bacilli.
In short, although absolute numbers and proportion clearly differ it seems likely that both replicating and non-replicating
bacilli are present in both latent infection and active disease.
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6infection, the risk is 12% over a person’s lifetime; if no disease
develops after 5 years the lifetime risk might only be 2% and
after 10 years 0.5%.
It is likely that at least in some people for whom there is a
prolonged time interval between infection and eventual
disease presentation, episodes of subclinical reactivation had
occurred much sooner. Evidence for this comes from
twentieth century mass chest radiograph (CXR) screening pro-
grammes, which identified asymptomatic persons with no
previous history of disease but with apical fibrotic scarring
felt to represent inactive or arrested TB. These individuals
were up to 15 times more likely to develop TB than those
having normal CXR, with the risk of developing TB steadily
falling over a 5–10 year period of observation [66]. In addition,
studies in Europe and America at a time of rapidly falling TB
incidence showed that up to 70% of persons developing TB
(with no history of TB and usually no clear contact history)
had evidence of fibrotic scarring on previous CXR [67,68].
This suggests that, in a proportion of people, the disease
may follow a cyclical waxing and waning course with earlier
reactivation initially arrested by the host delaying disease pres-
entation. In addition, it is clear that the subclinical phase of
active disease prior to clinical presentation may be several
months, as evidenced by the demonstration of culture positiv-
ity in asymptomatic persons. In HIV-infected persons in high
burden settings, prevalent asymptomatic TB has been shown
to be present in up to 8.5% [69].
(b) Immunosuppression
A number of conditions are associated with increased risk of
progression of TB,withHIV infection and anti-tumour necrosis
factor (TNF) therapy being two well-documented examples.
The effect of anti-TNF therapy is particularly striking in the
macaquemodel of latent TB treatment, with anti-TNF resulting
in almost universal reactivation in animals that had initially no
signs or symptoms of active disease for at least sixmonths from
the time of infection [70]. In humans treated with anti-TNF
therapy, especially with infliximab, the risk of TB is increased
initially up to 20-fold with 43% of TB cases occurring within
the first 90 days of administration of anti-TNF therapy, demon-
strating how rapidly active disease can be precipitated [71].
However, reactivation is by no means universal. In an evalu-
ation of the implementation of LTBI screening prior toanti-TNF therapy in Spain, 56 patients with positive TST
(more than 5 mm) were identified who did not receive any iso-
niazid prophylaxis and in only one case did TB occur following
anti-TNF treatment [72]. The impact of HIV on latent infection
can bemore challenging to evaluate as themajority of HIV/TB
studies areperformed inhighburden settingswhere reinfection
complicates understanding of the natural history of a single
infectious episode. In studies in low burden settings, wide-
spread ART use can also be a confounder. In addition and in
contrast to anti-TNF therapy, HIV-associated immunosuppres-
sion is slowly progressive. In studies from the high burden
setting of the South African mines, the risk of TB infection has
been shown to double within the first year, with Mtb strains
significantlymore likely to be uniquewithin 2 years ofHIV-ser-
oconversion than lateron in thedisease, suggesting that TBmay
more likely be precipitated by reactivation early in the course of
HIV and that recent reinfection with subsequent rapid pro-
gression occurs in more advanced immunosuppression [73].
Studies from low prevalence settings (Spain and Switzerland)
suggest that the rate of TB in HIV-infected persons who are
TST positive but untreated reduces over time, with most of
the excess cases of TB compared with TST negative occurring
within the first 2 years of follow-up; in total, only 10–12% of
this very high-risk group developed TB over a follow-up
period of up to 5 years [74,75].
(c) Protection from reinfection
Although latently infected persons are at greater risk of devel-
oping disease through reactivation than are those uninfected
there is some evidence that at least a proportion are protected
against subsequent (re)infection. Andrews et al. [76] reviewed
18 studies in which 19 886 persons with or without latent TB,
as evidenced by tuberculin reactivity, were followed up for
active disease in the absence of intervention. The majority of
these studies were published before 1950, and largely involved
nursing and medical students entering clinical practice and
exposed to extremely high annual rates of infection (median
33.6%). The incidence of disease in those with LTBI at entry
was 5.1/1000 person-years and in those uninfected at entry
was 18.2/1000 person-years. Once adjustments were made for
reactivation and average timing of infection, risk reduction in
those with LTBI was found to be 79%. Historical healthcare set-
tings clearly represent an extreme scenario, however other
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Figure 3. (a) Following infection, there may be a critical period where fate of infection is determined with predisposing factors (Prd) influencing this outcome. In a
small proportion, the primary infection may be progressive; in those that control primary infection, a proportion may eliminate TB or exert highly effective control
and be at very low risk of reactivation. In the third group, control may be unstable waxing and waning in response to a variety of precipitating factors (Prc) with
reactivation of TB most likely to occur in this high-risk group. (b) Precipitating factors (Prc) may lead to progression of disease. Prior to presentation these individuals
may pass through a subclinical phase of active infection which may last months; during this phase Mtb may be isolated by culture or pathology may be visible
through imaging prior to symptomatic presentation. (Online version in colour.)
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7approaches have also suggested a protective effect of infection.
Using national datasets over long periods of time to model the
dynamics of TB, Vynnycky & Fine [60] from data for England
and Wales 1900–1990 predicted a 16–41% protection from an
initial infection against reinfection, and Sutherland et al. [77]
from data for the Netherlands predicted 63–81% protection.
Taking an alternative strategy, Brooks-Pollock et al. [78] used
cross-sectional household data from Lima, Peru from 1996–
2002 to propose 35% protection. In detailed studies of reinfec-
tion in the rabbit model, Lurie [79] demonstrated that control
of a re-infecting strain in previously infected rabbits was
mediated by tissue resident mononuclear cells, with efficiency
of control relating to the extent of the primary lesion from the
initial infection. The mechanism of protection in humans is
not known but clearly an improved understanding of this
could greatly facilitate vaccine development.5. Integrating the spectrum of tuberculosis with
natural history
We and others have suggested that asymptomatic people
considered to have latent TB might be better considered
as part of a spectrum of infection states where at one endinfection may have been eliminated, while at the other end dis-
ease may be active but in a subclinical form, and between these
two extremes infection is controlled in a quiescent state [80–84].
When carefully considering the natural history of infection, it
seems plausible that soon after initial infection and immune
sensitization there are three main possible outcomes influenced
by predisposing factors that determine the course of infection
during this critical phase and alter the proportions in each
group (figure 3). Somemay initially develop primary progress-
ive disease; this may be a very small proportion in adults but
would likely be more common in advanced immunosuppres-
sion and infants. A second group (a high-risk group—the
main group from which reactivation disease arises) enter a
more unstable state with infection taking a waxing–waning
course during which periods of progression triggered by
precipitating factors may be followed by control (which may
lead to evidence of immunopathology) or the development of
clinical disease. Some precipitating factors may be more
potent than others; very potent precipitating factors (such as
anti-TNF and HIV) may have the effect of causing rapid pro-
gression over a short time interval. It is also in this group that
isoniazid preventive therapy may be most effective. A third
group may rapidly and effectively control infection and
eventually may even sterilize the organism and may be at
r8extremely low risk of progressing to active disease even in the
presence of precipitating factors.stb.royalsocietypublishing.org
Phil.Trans.R.Soc.B
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Somepredisposing andprecipitating factorsmayoverlap (figure
3). Many predisposing factors from the host side are known and
can be considered as generally immunosuppressive (HIV, mal-
nutrition, chronic kidney disease, type 2 diabetes mellitus, etc.)
but many more may be unknown, poorly characterized, have
more subtle effects andmayormay not be geneticallymediated.
In particular, rather than just immunosuppression alone it is
becoming more apparent that the extremes of the immune
response may lead to detrimental outcome in TB, with a more
balanced response being optimal (the so-called ‘Goldilocks
effect’);weak responsesmay lead tounopposedbacillary replica-
tion whereas aggressive responses may lead to tissue damage
andnecrosiswhichmayprovide amore favourable environment
for the bacillus.One of the implications of this,when considering
biomarker discovery for novel diagnostics (see below), is that
there may be at least two distinct correlates of risk.
Leukotriene (LT) A4 hydrolase (LTA4H) mediates the bal-
ance of pro-inflammatory eicosanoid LTB4 and anti-
inflammatory lipoxin A. Zebrafish larvae in which LTA4H is
over- or under-expressed are made hyper-susceptible to
Mycobacterium marinum infection compared with wild-type
either by low levels of LTA4H resulting in increased lipoxin A
and impaired TNFa production, or excessive LTA4H resulting
in increased LTB4 and increased TNFa production [85].
Humans who are heterozygous for a single-nucleotide poly-
morphism of LTA4H promoter rs17525495 (C/T) appear to
have the best clinical outcome from TB meningitis; those who
are homozygotes for the T allele (T/T) have increased LTA4H
expression and inflammatory cerebrospinal fluid, but derive
significantly greater benefit from dexamethasone therapy com-
pared with the C/C genotype [85–87]. In humans, plasma
prostaglandin E2 and lipoxin A levels likewise correlate with
disease susceptibility in a similar bimodal fashion with both
insufficient andabundant responses tied todisease exacerbation
(Mayer-Barber & Sher 2014, unpublished results, personal
communication).
Another intriguing and poorly understood predisposing
factor is age. It is a consistent and striking feature of TB that
the age of infection affects the risk of subsequently developing
disease [56,88]. Infants and young children, especially those
less than 2 years, are at considerable risk of developing disease
following infection. Older children (5–10 years old) have con-
sistently been shown to be at the lowest risk of TB following
infection especially, whereas peri-pubescent adolescents and
young adults are at much greater risk of developing cavitary
TB compared with children less than 10 years old [56,88]. It
has been suggested that thismay relate to the immunoendocrine
effects mediated by the balance between dehydroepiandroster-
one (DHEA—a precursor of sex steroids) and glucocorticoids
[89]. DHEA levels start increasing from 7 years old, peak in
early adulthood and reduce in older adults [88]. One of
DHEA’s many effects is as a glucocorticoid antagonist, and
the cortisol : DHEA ratio has important immunological conse-
quences. Recently, DHEA has been shown to influence
dendritic cell function to promote Th1 responses by increasing
interleukin (IL)-12 and diminishing IL-10 production following
Mtb stimulation, with increased expression of MHCI, MHCII
and CD86 expression resulting in enhanced T cell proliferationand IFNg production [90]. So it seemsplausible that pro-inflam-
matory responses in healthyadolescents and young adults have
detrimental effects leading to cavitary disease, anti-inflamma-
tory responses in infants lead to their inability to control
replication and there is a more optimal balanced response in
older children.
A further incompletely understood historical observation
recently being revisited is the effect of monocyte : lymphocyte
ratio (M : L) on risk of disease. It has been found in both
animal models and clinical observation that extremes of
both low and high M : L result in a greater risk of developing
TB, but what is still not clear is whether this is a predisposing
factor [91] or a marker of progressive disease as TB treatment
normalizes the M : L ratio [92].
While some precipitating factors may be well known
and potent resulting in rapid progression of the at risk group
(e.g. anti-TNF therapy), somemay just contribute to a fluctuating
course triggering disease in a minority. To consider an example,
an interesting observation is the seasonality of TBwith increased
case notification that can be 20–25% higher in spring/summer
compared with autumn/winter [93–96]. This is striking for an
infectious disease with relatively prolonged and variable incu-
bation. In common with other respiratory pathogens, one
explanation would be behavioural, with winter crowding lead-
ing to greater transmission, but modelling evidence and
analysis of unique and clustered Mtb strains suggest that this
cannot fully explain seasonalityof TB [97,98]. A seasonal precipi-
tating factor such as vitamin D deficiency or viral respiratory
infection (e.g influenza) is an alternative explanation. Vitamin
D, synthesized within the skin requiring UV light, acts as an
immunomodulatory and anti-inflammatory agent primarily
exerting its effect on the macrophage, facilitating enhanced con-
trol of mycobacteria through pleiotropic mechanisms [92,99]. A
number of clinical observations provide some support for the
role of vitaminDdeficiency in inducing reactivation. TB patients
arewell documented tohave significantly lower vitaminD levels
than healthy household controls [100,101], and the spring/
summer peak in TB notifications is preceded by a winter
trough invitaminD levels inCapeTown [102]. There is someevi-
dence to suggest that seasonality ismore pronounced in foreign-
born cases (who may be at greater risk of vitamin D deficiency
owing to skin tone) compared with native cases in Europe
[103,104].Analternative seasonalprecipitant couldbeviral infec-
tion. It has recently been shown that the type 2 interferon (IFNg)
response critical formycobacterial control canbe impairedby the
downstream effects of type 1 interferons (IFNa/b) [105]. It has
therefore been hypothesized that viral respiratory infections
inducing a type 1 interferon response could lead to reactivation
by impairment of type 2 interferon facilitated control of Mtb. In
the mouse model, mycobacterial growth is enhanced and survi-
val decreased in mice previously exposed to influenza by a
mechanism dependent on type 1 interferon signalling [106]. In
addition, historical observations andmodellingof the 1918 influ-
enza pandemic suggest a negative impact of influenza on TB
[107]. It is also possible that aside from host factors, variability
of the bacillusmay influence rate of progression anddisease out-
come, and it is worth noting that there is clear evidence for
diversifying selection in genes of the bacillus whose functional
roles are less than clear [108].
Having a fuller understanding of these predisposing and
precipitating factors and the magnitude of their effects might
allow us to consider the impact of novel intervention strat-
egies: for instance, whether widespread or targeted vitamin
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Figure 4. Acceptability of treatment relates to the duration and tolerability of
treatment and the likelihood of benefit ( prevention of progression to active dis-
ease). Improvements in drug regimens and/or improvements in predictability of
diagnostic tests should lead to improved acceptability of treating LTBI.
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9D replacement and/or influenza vaccination may impact the
incidence of TB.6. Novel diagnostic and preventive treatment
strategies for LTBI
Current approaches to management of latent TB centre on
those at greatest epidemiological risk of progressing to TB,
namely close contacts of active TB, HIV-infected and other
persons about to undergo, or with established, immunosup-
pression. Following diagnosis of latent TB, preventive
treatment is most commonly six to nine months of isoniazid
or a three month course of rifampicin or rifapentine and iso-
niazid [82] (in HIV-uninfected persons). However, in many
low- and middle-income countries with the highest burdens
of TB, many of these high-risk groups do not receive preven-
tive therapy, especially household contacts. In these settings,
operational research may enhance the better implementation
of clinical trials evidence and recommendations. However, to
make significant progress towards TB elimination will also
require providing preventive treatment to an even wider
group of latently infected persons. One of the critical barriers
to this is the acceptability of the current intervention to indi-
viduals at risk as well as healthcare professionals and policy
makers. This is to a large extent influenced by the prolonged
duration of treatment and the high NNT to prevent a case of
active disease; hence acceptability should improve if either
or both of these are improved (figure 4). An inexpensive
on-the-spot diagnostic that provided an accurate assessment
of likelihood of progression coupled with a single-dose
prophylactic would be game-changing for TB control and
enable mass testing and treatment programmes with a
realistic chance of achieving eradication.
More predictive diagnostic tests are a goal of TB research
agendas but how these tests might be implemented in practice
also requires careful evaluation. The perfect diagnostic for
latent TB would be a cheap, low resource, point-of-care testwith very high positive and negative predictive value that
maintained sensitivity in immunocompromised persons,
notably HIV infection and children. However, it is worth
noting that a single test cannot be both highly predictive for
active TB and a sensitive marker of exposure as these test
characteristics are to a degree a mutually exclusive. Another
consideration is over what period of time should these tests
be predictive? It may be substantially easier to develop tests
(from both a development and validation perspective) that
are predictive over a short period of time—e.g. risk over 12
months rather than predictive of life time risk—as it may be
over this time frame that transition into a subclinical phase
prior to symptomatic presentation occurs with characteristic
changes in the host response and bacillary numbers and meta-
bolic state. Such shorter term predictive tests may be of
particular use in high burden settings where reinfection is
common and in HIV-infected persons and other immunocom-
promised groups (such as in type 2 diabetes mellitus and
chronic renal failure) where regular contact with healthcare
many allow for regular screening. In addition, recent contacts
of TB could be followedup annually during the period of great-
est risk. Optimal test characteristics might change as the
elimination phase progresses; understanding these require-
ments will be helped greatly by models showing the impact
of different types of tests in different settings.
(a) Markers of exposure
As discussed, TST and IGRA are poorly predictive but also
are suboptimal measures of Mtb exposure. Both TST and
IGRA show evidence of spontaneous reversion over time
and hence some people previously exposed to and immune
sensitized by Mtb may have a negative test. A proportion
of these individuals may be identified using a two-step test-
ing strategy where the initial negative TST boosts the
immune response so subsequent TST or IGRA reverts to posi-
tive [109]. In addition, the sensitivity of TST and IGRA for
active TB infection is only 70–90% [110–112]; not withstand-
ing arguments as to why immunodiagnostic tests might be
compromised in someone with active TB, a test that is not
able to identify the most heavily infected individuals leaves
room for improvement. A more sensitive test for Mtb
exposure would give a better understanding of TB trans-
mission dynamics and more accurate estimation of the
annual rate of infection. Because IGRAs detect IFN-g pro-
duction after short-term incubation (16–24 h), they identify
primarily ESAT6/CFP10-specific effector cells and it is poss-
ible that prolonged assays measuring alternative cytokines or
flow cytometric assays could identify central memory popu-
lations that may be a better marker of exposure and history of
immune sensitization than the currently available tests.
(b) Predictive markers
Predictive biomarkers could be developed using two broad
approaches. Careful follow-up of an at-risk population over
time during which some develop TB might allow identifi-
cation of biomarkers that were correlates of risk, although
such natural history approaches would not only require
very large numbers but would also have considerable ethical
considerations unless carried out in groups where obser-
vation is standard of care, such as contacts of multi-drug
resistant (MDR)-TB, where guidelines do not recommend
preventive therapy (e.g. over 35-year-olds in some countries)
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10or in placebo arms of intervention studies. Another approach
would be to identify biomarkers for people at the transition
of latent to active disease with subclinical and minimally
active pathology or evidence of immunopathology (e.g. fibro-
tic scaring) and then validate these markers prospectively.
The most useful predictive biomarkers will most likely be
mycobacterial products or markers of host response ident-
ified within blood or urine or through skin testing. ‘Omics’
approaches are useful as exploratory tools to identify key
components of diagnostic tests; transcriptomic approaches
have been particularly successful at differentiating the
extremes of active and latent TB [113,114], but these signa-
tures may not be predictive of active TB if the signatures
relate to response to disease process itself. More predictive
tests would certainly be a huge advance allowing treatment
decisions to be based on a biological as well as epidemiologi-
cal markers of risk, but it is sobering to note how slow
progress in the cancer field has been in developing markers
of early detection into diagnostic tests. Such biomarkers
will be challenging to develop, requiring a large amount of
support to move down the pipeline from concept through
to development, validation and implementation; but unlike
vaccine, drug and diagnostic tests for active TB, no such
pipeline exists for predictive tests for latent TB.(c) Drugs
Shorter drug regimens are highly desirable for treatment of
both latent and active TB, with the current prolonged treatment
duration required to ensure that recrudescence of persisting
organisms does not occur after cessation of therapy. In addition,
a prolonged treatment course is associated with poor treatment
adherence in routine settings. Drugs that contribute most to
treatment shortening of active or latent TB (rifampicin and pyr-
azinamide) have the most potent sterilizing ability (usually
determined by evaluating relapse rate in the murine model),
whereas isoniazid, although rapidly bactericidal, largely acts
on replicating bacilli and has poor sterilizing activity [115]. As
an alternative strategy to shortening treatment for LTBI, rather
than targeting persisting organisms, might be to provoke resus-
citation of non-replicating bacilli and couple this with rapidly
bactericidal therapies such as isoniazid. Such approaches will
require a far more sophisticated understanding of the mechan-
isms of resuscitation and ability to define themetabolic states of
single organisms.
The optimal duration of isoniazid as preventive therapy is
nine months [116]; with addition of rifampicin or rifapentine
this reduces to three months and rifampicin combined with
pyrazinamide is effective after two months of administration
(although unacceptable toxicity prevents widespread use of
this regimen) [117]. There are several novel or re-purposed
drugs in later stages of the TB drug pipeline [118] that have
impressive sterilizing ability either alone or in drug combi-
nations (usually in pyrazinamide-containing regimens).
Bedaqualine (recently FDA approved for active MDR-TB) and
sutezolid (an oxalozidinone in phase 2 studies) seem most
promising in this respect. Nitroimidazole derivatives (delama-
nid and PA-824) and moxifloxacin are also possibilities [119].
Whether reductions in treatment duration beyond two months
could be feasible is not certain, however it is possible that this
pipeline provides several options for preventive treatment in
drug-resistant TB contacts. Amajor consideration for novel regi-
mens in addition to cost [120] is toxicity and side effects, whichare a major factor when treating otherwise asymptomatic per-
sons (as demonstrated by pyrazinamide), especially while we
are unable to more precisely define who will derive greatest
benefit from preventive therapy.
A further challenge is how to best evaluate novel LTBI regi-
mens. Currently, the only endpoint for clinical trials is the
absence of disease and hence in order to demonstrate clinical
efficacy studies they will need large numbers and prolonged
follow-up. A surrogate marker of clinical response (analogous
to 14-day early bactericidal activity or two-month culture con-
version for active TB) may allow for more rapid evaluation of
different regimens to select which should go forward to
larger clinical studies. Peripheral blood biomarkers that signify
treatment success for LTBI would be very useful in this regard.
An alternative approach that is being developed similar to
oncology studies is the use of PET/CT imaging to evaluate
response of therapy. 18F-Fluorodeoxyglucose (FDG) is the
most widely used tracer, is a non-specific marker of metabolic
activity and is taken up avidly by activated neutrophils and
macrophages [121]. Sites of active TB even in the absence of
symptoms accumulate FDG avidly and a number of studies
have demonstrated that uptake is markedly reduced following
TB treatment [122–125]. Tracers that are more specific for Mtb
would be a great advance and these are currently in early
stages of development.(d) Post-exposure vaccines and immunomodulation
TB vaccines can be administered either pre-infection, designed
to prevent infection from occurring, or post-infection, designed
to prevent latent infection progressing. H56 is amultistage vac-
cine comprising the Ag85B, ESAT-6 and Rv2660 antigens, is
one of the first vaccines to be designed to be used post-infec-
tion, and is soon entering phase I/IIa studies in South Africa
in latently infected and uninfected adults [126].
However, recently the MVA85A vaccine, a novel TB vac-
cine (administered pre-infection) that was in the most
advanced stage of clinical development, yielded disappoint-
ing results that demonstrated safety but no significant
efficacy over placebo in preventing TB when administered
to BCG-vaccinated, HIV-negative infants with no evidence
of latent TB infection, in a high burden setting [127]. The
resulting debate has highlighted how limited our under-
standing of protective immunity in humans is and the
dangers of extrapolating findings in animal models to clinical
practice [128]. Our understanding of how to use a vaccine to
safely prevent reactivation of an established latent infection is
even more limited, as there are fewer appropriate animal
models and there is always concern about the induction of
Koch reactions, where rapid induction of vigorous immune
response in persons with an asymptomatic subclinical infec-
tion may result in immunopathology and symptomatic
deterioration. It is critical that we develop a better under-
standing of what the immunological correlates of protection
from disease are in humans to inform vaccine design. One
approach may be in the careful evaluation of the hetero-
geneous effects of vaccination either within a single trial or
between trials performed in different populations and the
correlation with clinical outcomes. Another approach would
be to try and better understand the protective effects of natu-
ral infection especially the immunological basis for this (see
above), or to characterize the immunological differences in
response to infection between older children and young
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infection, respectively (see above). In particular, if we are to
develop vaccines that prevent reactivation or successfully
eliminate latent infection, we need to better understand
the immunological mechanisms that precipitate reactivation
and control in those with unstable latent infection, which
may require refinement of existing animal models to more
accurately reflect the natural history of TB in humans.
An alternative and innovative approach would be to com-
bine immunomodulation with anti-tuberculous treatment as a
method to shorten therapy. This immunomodulation could
take the form of either a vaccine or a drug. RUTI is a novel vac-
cine comprising heat inactivated, liposomed fragments of Mtb
grown under different conditions of stress designed to
be administered after one month of chemotherapy of LTBI
and facilitate immune clearance of persisting bacilli [129].
The vaccine is currently in phase 2 studies in HIV-infected
and -uninfected persons with LTBI (http://clinicaltrials.gov/
show/NCT01136161)01304377. Concluding remarks
A coordinated strategy will be required to effectively tackle
the reservoir of latent infection. Improved data are needed
to more accurately estimate the scale of the problem andquantify the number of new infections occurring each year,
and a redoubling of effort will be required to reduce this as
far as possible by implementing currently recommended
interventions. However, in order for widespread treatment
of latent TB to be acceptable to the public, healthcare provi-
ders and policy makers, major advances on the currently
available diagnostic and interventional tools will be required.
Progress in identifying who is most likely to reactivate and
how this occurs will assist the development of more predic-
tive diagnostic tests allowing interventions to be focused on
those that will benefit most. The development of drugs that
effectively target and rapidly sterilize the subset of persistent
bacilli should allow for significant reductions in the duration
of preventive treatment. Both of these should improve accept-
ability of more widespread treatment of latent infection. In
addition, greater understanding of who is protected from
reinfection and how this occurs would provide key pieces
of knowledge to facilitate progress with development of
effective vaccines and immunomodulatory agents that
could have a major impact.
The aim to eliminate TB by 2050 is a bold one and the
development of the post-2015 TB strategy and targets pro-
vides an opportunity to identify the critical gaps in our
knowledge and to focus the scientific community, policy
makers, advocates and funding agencies on achieving this
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